Ariadne Wealth Management LP Purchases Shares of 358 Humana Inc. (NYSE:HUM)

Ariadne Wealth Management LP purchased a new stake in shares of Humana Inc. (NYSE:HUM) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 358 shares of the insurance provider’s stock, valued at approximately $134,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HUM. Pzena Investment Management LLC lifted its position in shares of Humana by 538.7% during the 2nd quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock valued at $866,250,000 after acquiring an additional 1,955,375 shares during the last quarter. Ontario Teachers Pension Plan Board lifted its position in shares of Humana by 11,647.2% during the 1st quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock valued at $367,342,000 after acquiring an additional 1,050,459 shares during the last quarter. Marshall Wace LLP lifted its position in shares of Humana by 118.9% during the 2nd quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after acquiring an additional 774,085 shares during the last quarter. Putnam Investments LLC lifted its position in shares of Humana by 550.3% during the 4th quarter. Putnam Investments LLC now owns 875,489 shares of the insurance provider’s stock valued at $400,808,000 after acquiring an additional 740,858 shares during the last quarter. Finally, Steadfast Capital Management LP acquired a new stake in shares of Humana during the 1st quarter valued at $158,813,000. 92.38% of the stock is owned by institutional investors.

Humana Trading Down 11.8 %

Humana stock opened at $279.42 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. The company has a market capitalization of $33.67 billion, a price-to-earnings ratio of 17.40, a PEG ratio of 2.44 and a beta of 0.50. Humana Inc. has a one year low of $276.80 and a one year high of $530.54. The company’s fifty day moving average price is $346.44 and its two-hundred day moving average price is $343.73.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping the consensus estimate of $5.89 by $1.07. The firm had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the business posted $8.94 earnings per share. On average, analysts forecast that Humana Inc. will post 16.01 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.27%. The ex-dividend date is Monday, September 30th. Humana’s payout ratio is 22.04%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Royal Bank of Canada increased their price objective on Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, September 5th. Piper Sandler assumed coverage on Humana in a report on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 target price for the company. Oppenheimer increased their target price on Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Cantor Fitzgerald restated a “neutral” rating and issued a $395.00 target price on shares of Humana in a report on Tuesday. Finally, TD Cowen increased their target price on Humana from $396.00 to $407.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Thirteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $398.70.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.